

BIBLIOGRAPHY

- Asad, M., Karim, S., Sanobar, Khan, M.F., Ansari, W.A., Said, Y.A., Khan, M.I., Saquib, M. and Hussain, M.K., 2024, Synthesis and Evaluation of 3,5-Disubstituted-1,2,4-Oxadiazolyl Benzamides as Potential Anti-Breast Cancer Agents: In Vitro and In Silico Studies, *Chem. Biodiv.*, 22(3).
- Ashrafizadeh, M., Ahmadi, Z., Mohammadinejad, R., & Afshar, E. G., 2020, Tangeretin: A Mechanistic Review of its Pharmacological and Therapeutic Effects, *J. Basic Clin. Physiol. Pharmacol.*, 31(2), 1–13.
- Azam, S.S., Uddin, R. and Wadood, A., 2012, Structure and Dynamics of Alpha-Glucosidase through Molecular Dynamics Simulation Studies, *J. Mol. Liq.*, 174(2012), 58–62.
- Azmal, M., Paul, J. K., Prima, F. S., Talukder, O. F., & Ghosh, A., 2024, An In Silico Molecular Docking and Simulation Study to Identify Potential Anticancer Phytochemicals Targeting the RAS Signaling Pathway, *PLoS ONE*, 19(9), e0310637.
- Bornscheuer, U.T. and Höhne, M., 2018, Protein Engineering: Methods and Protocols, Humana Press, New York.
- Case, D.A., Cheatham, T.E., Darden, T., Gohlke, H., Luo, R., Merz, K.M., Onufriev, A., Simmerling, C., Wang, B. and Woods, R.J., 2005, The Amber Biomolecular Simulation Programs, *J. Comp. Chem.*, 26(16), 1668–1688.
- Chaikuad, A., Tacconi, E., Zimmer, J., Liang, Y., Gray, N. S., Tarsounas, M., & Knapp, S., 2014, A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics, *Nat. Chem. Biol.*, 10(10), 853–860.
- Chen, F., Hancock, C.N., Macias, A.T., Joh, J., Still, K., Zhong, S., MacKerell, A.D. Jr. and Shapiro, P., 2006, Characterization of ATP-Independent ERK Inhibitors Identified Through In Silico Analysis of the Active ERK2 Structure, *Bioorg. Med. Chem. Lett.*, 16(24), 6281–6287.
- Dewar, M.J.S., Zoebisch, E.G., Healy, E.F. and Stewart, J.J.P., 1985, Development and Use of Quantum Mechanical Molecular Models. 76. AM1: a New General Purpose Quantum Mechanical Molecular Model, *J. Amer. Chem. Soc.*, 107(13), 3902–3909.
- Fan, J., Fu, A., & Zhang, L., 2019, Progress in Molecular Docking, *Protein Cell*, 10(6), 417–432.
- Flachsenberg, F., Ehrt, C., Gutermuth, T., & Rarey, M., 2023, Redocking the PDB, *J. Chem. Inf. Model.*, 63(24), 8110–8123.

- Foulkes, W.D., Smith, I.E. and Reis-Filho, J.S., 2010, Triple-Negative Breast Cancer, *N. Engl. J. Med.*, 363(20), 1938–1948.
- Gagliardi, M., Pitner, M.K., Park, J., Xie, X., Saso, H., Larson, R.A., Sammons, R.M., Chen, H., Wei, C., Masuda, H., Chauhan, G., Kondo, K., Tripathy, D., Ueno, N.T., Dalby, K.N., Debeb, B.G. and Bartholomeusz, C., 2020, Differential Functions of ERK1 and ERK2 in Lung Metastasis Processes in Triple-Negative Breast Cancer, *Sci. Rep.*, 10(1).
- Hanahan, D. and Weinberg, Robert A., 2011, Hallmarks of Cancer: the Next Generation, *Cell*, 144(5), 646–674.
- Hevener, K.E., Zhao, W., Ball, D.M., Babaoglu, K., Qi, J., White, S.W. and Lee, R.E., 2009, Validation of Molecular Docking Programs for Virtual Screening against Dihydropteroate Synthase, *J. Chem. Inf. Model.*, 49(2), 444–460.
- Hollingsworth, S. A., and Dror, R. O., 2018, Molecular Dynamics Simulation for All, *Neuron*, 99(6), 1129–1143.
- Kanehisa, M. and Goto, S., 2000, KEGG: Kyoto Encyclopedia of Genes and Genomes, *Nucleic Acids Res.*, 28(1), 27–30.
- Kroemer, R. T., 2004, Structure-Based Drug Design: Docking and scoring, *Curr. Prot. Pept. Sci.*, 5(5), 425–437.
- Kustiawan, P.M., Siregar, K.A.A.K., Jauhar, M.M., Ramadhan, D., Mardiyati, E. and Syaifie, P.H., 2024, Network Pharmacology and Bioinformatic Integrative Analysis Reveals Candidate Gene Targets and Potential Therapeutic of East Kalimantan Propolis against Hepatocellular Carcinoma, *Heliyon*, 10(21), e39142.
- Lakshmi, A. and Subramanian, S., 2014, Chemotherapeutic Effect of Tangeretin, a Polymethoxylated Flavone Studied in 7, 12-dimethylbenz(a)anthracene Induced Mammary Carcinoma in Experimental Rats, *Biochimie*, 99, 96–109.
- Liu, C.-H., Xu, M., Du, J., Ni, Y., Luo, Q., Wang, Z., Tan, W., He, Y., Zhang, L., Jia, X., & Zhao, X., 2025, Synthesis of the polymethoxyflavones nobiletin, tangeretin, isosinensetin, and gardenin A–D, *Org. Biomol. Chem.*, 23(11), 2597–2600.
- Mace, P. D., Wallez, Y., Egger, M. F., Dobaczewska, M. K., Robinson, H., Pasquale, E. B., & Riedl, S. J., 2013, Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK, *Nat. Commun.*, 4, 1681.

- Mayer, M., Wilson, P., & Schomburg, D., 1996, Hydrogen Bonding and Molecular Surface Shape Complementarity as a Basis for Protein Docking, *J. Mol. Biol.*, 264(1), 199–210.
- Manthey, J.A. and Guthrie, N., 2002, Antiproliferative Activities of Citrus Flavonoids against Six Human Cancer Cell Lines, *J. Agric. Food Chem.*, 50(21), 5837–5843.
- Maik-Rachline, G., Hacoheh-Lev-Ran, A. and Seger, R., 2019, Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer, *Int. J. Mol. Sci.*, 20(5), 1194.
- Meng, E. C., Shoichet, B. K., and Kuntz, I. D., 2011, Automated Docking with Grid-Based Energy Evaluation, *J. Comp. Chem.*, 23(15), 1175–1189.
- Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J., 2009, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, *J. Comput. Chem.*, 30(16), 2785–2791.
- Morris, G. M., and Lim-Wilby, M., 2008, Molecular Docking, *Meth. Mol. Bio.*, 443, 365–382.
- Ohuri, M., Kinoshita, T., Okubo, M., Sato, K., Yamazaki, A., Arakawa, H., Nishimura, S., Inamura, N., Nakajima, H., Neya, M., Miyake, H. and Fujii, T., 2005, Identification of a Selective ERK Inhibitor and Structural Determination of the Inhibitor–ERK2 Complex, *Biochem. Biophys. Res. Commun.*, 336, 357–363.
- Ohuri, M., Kinoshita, T., Yoshimura, S., Warizaya, M., Nakajima, H., & Miyake, H., 2007, Role of a cysteine residue in the active site of ERK and the MAPKK family, *Biochem. Biophys. Res. Commun.*, 353(3), 633–637.
- Paggi, J. M., Pandit, A., & Dror, R. O., 2024, The Art and Science of Molecular Docking, *Annu. Rev. Biochem.*, 93(1), 389–410.
- Pathania, S., Singh, P. K., Narang, R. K., & Rawal, R. K., 2021, Structure based designing of thiazolidinone-pyrimidine derivatives as ERK2 inhibitors: Synthesis and in vitro evaluation. *SAR QSAR Environ. Res.*, 32(10), 793–816.
- Periyasamy, K., Baskaran, K., Ilakkia, A., Vanitha, K., Selvaraj, S. and Sakthisekaran, D., 2014, Antitumor Efficacy of Tangeretin by Targeting the Oxidative Stress Mediated on 7,12-dimethylbenz(a) Anthracene-Induced Proliferative Breast Cancer in Sprague–Dawley Rats, *Cancer Chemother. Pharmacol.*, 75(2), 263–272.

- Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E., 2004, UCSF Chimera—A Visualization System for Exploratory Research and Analysis, *J. Comp. Chem.*, 25(13), 1605-1612.
- Raza, W., Luqman, S., Meena, A., 2020, Prospects of Tangeretin as a Modulator of Cancer Targets/Pathways, *Pharmacol. Res.*, 161, 105202.
- Roskoski, R., 2012, ERK1/2 MAP Kinases: Structure, Function, and Regulation, *Pharmacol. Res.*, 66(2), 105–143.
- Safe, S., Jayaraman, A., Chapkin, R.S., Howard, M., Mohankumar, K. and Shrestha, R., 2021, Flavonoids: Structure–Function and Mechanisms of Action and Opportunities for Drug Development, *Toxicol. Res.*, 37(2), 147–162.
- Sah, V. K., Singh, A. K., Kumar, A., Prajapati, V., Kalsi, A., Khalilullah, H., Jaremko, M., Emwas, A.-H., Verma, A., & Kumar, P., 2025, Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation, *J. Enzym. Inhib. Med. Chem.*, 40(1).
- Sajal, H., Patil, S. M., Raj, R., Shbeer, A., Ageel, M., & Ramu, R., 2022, Computer-Aided Screening of Phytoconstituents from *Ocimum tenuiflorum* against Diabetes Mellitus Targeting DPP4 Inhibition: A Combination of Molecular Docking, Molecular Dynamics, and Pharmacokinetics Approaches, *Mol.*, 27(16), 5133–5133.
- Siegel, R.L., Giaquinto, A.N. and Jemal, A., 2024, Cancer Statistics, 2024, *CA Cancer J. Clin.*, 74(1), 12–49.
- Sousa, S.F., Fernandes, P.A. and Ramos, M.J., 2006, Protein-Ligand Docking: Current Status and Future Challenges, *Proteins: Struct. Funct. Bioinf.*, 65(1), 15–26.
- Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., Wang-Gillam, A., Sznol, M., Flaherty, K., Buchbinder, E., Carvajal, R. D., Varghese, A. M., Lacouture, M. E., Ribas, A., Patel, S. P., & DeCrescenzo, G. A., 2017, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study, *Cancer Discov.*, 8(2), 184–195.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, *CA Cancer J. Clin.*, 71(3), 209–249.

- Taylor, C. A., Cormier, K. W., Martin-Vega, A., Earnest, S., Stippec, S., Wichaidit, C., & Cobb, M. H., 2023, ERK2 Mutations Affect Interactions, Localization, and Dimerization, *biochem.*, 62(51), 4991–5003.
- The Cancer Genome Atlas Network, 2012, Comprehensive Molecular Portraits of Human Breast Tumours, *Nature*, 490, 61–70.
- Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A. and Case, D.A., 2004, Development and Testing of a General Amber Force Field, *J. Comp. Chem.*, 25(9), 1157–1174.
- Wang, W., Jia, T., Zhang, Y. and Zhou, Y., 2024, Progress of Researches on Pharmacological Effects and Bioavailability of Tangeretin, *J. Oleo Sci.*, 74(1), 13–23.
- Ward, R. A., Colclough, N., Challinor, M., Debreczeni, J., Eckersley, K., Fairley, G., Feron, L., Flemington, V., Graham, M. A., Greenwood, R., Hopcroft, P., Howard, T. D., James, M. J., Jones, C. D., Jones, C. R., Renshaw, J., Roberts, K., Snow, L., Tonge, M., & Yeung, K. T., 2015, Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2, *J. Med. Chem.*, 58(11), 4790–4801.
- Xu, Y., Yan, X., Zhuang, J. and Hao, H., 2025, The Anticancer Perspective of Tangeretin: A Small Review, *Molecules*, 30(2), 300.
- Yap, J.L., Worlikar, S., MacKerell, A.D. Jr., Shapiro, P. and Fletcher, S., 2011, Small Molecule Inhibitors of the ERK Signalling Pathway: Towards Novel Anti-Cancer Therapeutics, *ChemMedChem*, 6(1), 38–48.
- Zhytnyaktivska, O., Malovytsia, U., Vus, K., Trusova, V., & Gorbenko, G., 2025, Interaction of Heavy Metals with 7S Soybean Globulin: Molecular Dynamics Study, *East Eur. J. Phys.*, 1, 403–410.